IP Library Granted Patent US 8,076,476
Granted Patent B2
US 8,076,476 · App. 12/271,040 · Granted Dec 13, 2011

Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,076,476
App. No.
12/271,040
Granted
Dec 13, 2011
Kind
B2
Abstract

Morpholino compounds are provided having the structure: where R 1 is selected from the group consisting of lower alkyl, di(lower alkyl)amino, and phenyl; R 2 is selected from the group consisting of lower alkyl, monocyclic arylmethyl, and monocyclic (aryloxy)methyl; R 3 is selected from the group consisting of triarylmethyl and hydrogen; and Y is selected from the group consisting of: a protected or unprotected hydroxyl or amino group; a chlorophosphoramidate group; and a phosphorodiamidate linkage to the ring nitrogen of a further morpholino compound or a morpholino oligomer. Such compounds include doubly protected morpholino guanine (MoG) monomers. Also described is their use in synthesis of morpholino oligomers.

Claims (35)

1. A morpholino compound having the following structure I:

wherein:

R 1 is lower alkyl, di(lower alkyl)amino or phenyl;

R 2 is lower alkyl, monocyclic arylmethyl or monocyclic (aryloxy)methyl;

R 3 is triarylmethyl or hydrogen; and

Y is a protected or unprotected hydroxyl group, a protected or unprotected amino group, a chlorophosphoramidate group, a phosphorodiamidate linkage to the morpholino ring nitrogen of a morpholino subunit monomer, a phosphorodiamidate linkage to the morpholino ring nitrogen of a morpholino subunit in a morpholino oligomer or a linkage to a solid support.

2. The compound of claim 1 , wherein Y is a protected or unprotected hydroxyl group or a chlorophosphoramidate group.

3. The compound of claim 2 , wherein Y is a trialkylsilyl-protected hydroxyl group or an unprotected hydroxyl group.

4. The compound of claim 2 , wherein Y is a chlorophosphoramidate group having the following structure:

5. The compound of claim 1 , wherein R 3 is trityl, 4-methoxytrityl, 4-methyltrityl, 4,4′-dimethyltrityl or 4,4′,4″-trimethyltrityl.

6. The compound of claim 1 , wherein R 1 is lower alkyl.

7. The compound of claim 6 , wherein R 1 is —C(CH 3 ) 3 .

8. The compound of claim 1 , wherein R 2 is benzyl or —CH(CH 3 ) 2 .

9. A method of synthesizing a morpholino oligomer, the method comprising:

(a) reacting

a solid-phase-supported morpholino subunit monomer comprising an unprotected morpholino ring nitrogen

with a first morpholino subunit monomer comprising a triarylmethyl-protected morpholino ring nitrogen and an activated phosphoramidate group on a 5′-exocyclic carbon, thereby forming a phosphorodiamidate linkage between the 5′-exocyclic carbon of the first morpholino subunit monomer and the unprotected morpholino ring nitrogen of the solid-phase-supported morpholino subunit monomer;

(b) deprotecting the triarylmethyl-protected morpholino ring nitrogen to form a product comprising an unprotected morpholino ring nitrogen;

(c) optionally reacting the product from step (b) with a further morpholino subunit monomer comprising a triarylmethyl-protected morpholino ring nitrogen and an activated phosphoramidate group on a 5′-exocyclic carbon, thereby forming a phosphorodiamidate linkage between the 5′-exocyclic carbon of the further morpholino subunit monomer and the unprotected morpholino ring nitrogen of the product from step (b); and

(d) optionally repeating steps (b) and (c) one or more times;

wherein at least one of the first morpholino subunit monomer, the further morpholino subunit monomer or the solid-phase-supported morpholino subunit monomer is a doubly protected guanine morpholino compound having the following structure I:

wherein:

R 1 is lower alkyl, di(lower alkyl)amino or phenyl;

R 2 is lower alkyl, monocyclic arylmethyl or monocyclic (aryloxy)methyl;

R 3 is triarylmethyl or hydrogen; and

Y is a chlorophosphoramidate group or a linkage to a solid support.

10. The method of claim 9 , wherein Y is a chlorophosphoramidate group having the following structure:

11. The method of claim 9 , wherein R 3 is trityl, 4-methoxytrityl, 4-methyltrityl, 4,4′-dimethyltrityl or 4,4′,4″-trimethyltrityl.

12. The method of claim 9 , wherein R 1 is lower alkyl.

13. The method of claim 12 , wherein R 1 is —C(CH 3 ) 3 .

14. The method of claim 9 , wherein R 2 is benzyl or —CH(CH 3 ) 2 .

15. The compound of claim 1 , wherein the compound has the following structure:

wherein Y is a linkage to a solid support or a chlorophosphoramidate group having the following structure:

16. The method of claim 9 , wherein at least one of the first morpholino subunit monomers, the further morpholino subunit monomer or the solid-phase-supported morpholino subunit monomer has the following structure:

wherein Y is a linkage to a solid support or a chlorophosphoramidate group having the following structure:

Assignments (3)
SECURITY INTEREST Recorded May 7, 2025
From: SAREPTA THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 071218/0445 →
CHANGE OF NAME Recorded May 30, 2019
From: AVI BIOPHARMA, INC.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 049315/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2009
From: REEVES, MATTHEW DALE; WELLER, DWIGHT D.; LI, YONGFU
To: AVI BIOPHARMA, INC.
Reel/Frame 022794/0061 →